Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Generic Vonoprazan 20 mg vs Vocinti 20 mg in Healthy Thai Volunteers (Fasting)
TCTR20251127001Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonoprazan (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
vonoprazan
Beyond the preview
Go deeper on TCTR20251127001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251127001.